SCHEMBL5258739

SCHEMBL5258739

Cn1c(=S)oc2cc(C=O)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 5/20 0.44
▸ ALDH1A1 P00352 8/20 0.35
▸ HPGD P15428 3/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ PTGER4 P35408 3/20 0.35
▸ MAPT P10636 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ MDM2 Q00987 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027286 0.81 ALDH1A1 (0.50) CYP2A6ALDH1A1HPGDLMNATSHR
SCHEMBL18386658 0.75 MIF (0.46) ALDH1A1HPGDHSD17B10MAPK1MAPT
SCHEMBL16172323 0.71 KCNH2 (0.36) ALDH1A1HPGDHSD17B10MAPK1MAPT
SCHEMBL5252911 0.69 ALDH1A1 (0.47) ALDH1A1HPGDMAPTRAB9ANPC1
SCHEMBL31711447 0.69 CYP2A6 (0.53) CYP2A6ALDH1A1HPGDHSD17B10PTGER4
SCHEMBL2713434 0.69 CYP2A6 (0.53) CYP2A6ALDH1A1HPGDHSD17B10PTGER4
SCHEMBL19512778 0.68 CYP2A6 (0.45) CYP2A6ALDH1A1HPGDLMNATSHR
SCHEMBL8698045 0.67 ALDH1A1 (0.56) ALDH1A1HPGDHSD17B10MAPK1MAPT
SCHEMBL18720407 0.66 CYP2A6 (0.50) CYP2A6ALDH1A1HPGDHSD17B10PTGER4
SCHEMBL1525859 0.66 ALDH1A1 (0.55) CYP2A6ALDH1A1HPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES UNIV WAYNE STATE (US) 2017-01-19 — — US disclosed
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES UNIV WAYNE STATE (US) 2017-01-19 — — US disclosed
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES UNIV WAYNE STATE (US) 2017-01-19 — — US disclosed
US-9458124-B2 Substituted pyran derivatives WAYNE STATE UNIVERSITY (US) 2016-10-04 — — US disclosed
US-9458124-B2 Substituted pyran derivatives WAYNE STATE UNIVERSITY (US) 2016-10-04 — — US disclosed
US-9458124-B2 Substituted pyran derivatives WAYNE STATE UNIVERSITY (US) 2016-10-04 — — US disclosed
US-20140309427-A1 Substituted Pyran Derivatives NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-10-16 — — US disclosed
US-20140309427-A1 Substituted Pyran Derivatives NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-10-16 — — US disclosed
US-20140309427-A1 Substituted Pyran Derivatives NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-10-16 — — US disclosed
EP-1359908-B1 QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2007-08-22 — — EP disclosed
US-7205408-B2 Quinolines and nitrogenated derivative thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents SMITHKLINE BEECHAM, P.L.C. (GB) 2007-04-17 — — US disclosed
US-20040138219-A1 Quinolines and nitrogenated derivative therof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents SMITHKLINE BEECHAM P.L.C. (GB) 2004-07-15 — — US disclosed
EP-1359908-A1 QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-11-12 — — EP disclosed
WO-2002056882-A1 QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES SLC18A2, SLC6A4, SLC6A3 CYP2A6 219/4885ALDH1A1 772/4885HPGD 686/4885
US-20140309427-A1 Substituted Pyran Derivatives SLC18A2, SLC6A4, SLC6A3 CYP2A6 219/4885ALDH1A1 772/4885HPGD 686/4885
US-20040138219-A1 Quinolines and nitrogenated derivative therof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents NCF1, TEAD1, TYMS CYP2A6 1885/4885ALDH1A1 1742/4885HPGD 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback